Pharmacosmos A/S Acquires AbFero Pharmaceuticals, Inc.
November 11, 2021
Pharmacosmos A/S (Pharmacosmos Group) has agreed to acquire all assets of Boston-based clinical-stage AbFero Pharmaceuticals, Inc. under a share purchase agreement for up to $225 million including upfront, milestone, and royalty components. The acquisition adds AbFero’s SP-420 iron chelation program to Pharmacosmos’ iron-metabolism-focused R&D and commercial capabilities to accelerate development and commercialization for transfusional iron overload and related indications.
- Buyers
- Pharmacosmos A/S
- Targets
- AbFero Pharmaceuticals, Inc.
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Pharmacosmos Acquires G1 Therapeutics
August 7, 2024
Biotechnology
Pharmacosmos A/S, through its U.S. affiliate Pharmacosmos Therapeutics Inc., agreed to acquire all outstanding shares of G1 Therapeutics, Inc. for $7.15 per share in cash, implying an approximate equity value of $405 million. The deal brings G1's FDA-approved oncology product COSELA into Pharmacosmos' commercial portfolio to accelerate patient access and expand Pharmacosmos' presence in oncology and supportive care.
-
FMC Corporation Acquires BioPhero ApS
June 30, 2022
Agriculture
FMC Corporation will acquire Danish pheromone producer BioPhero ApS from Novo Holdings for approximately USD 200 million. The deal expands FMC’s biologicals platform by adding BioPhero’s cost-efficient biotechnology process for pheromone production; BioPhero will remain headquartered in Copenhagen and the transaction was expected to close by end of Q3 2022.
-
MorphoSys Acquires Constellation Pharmaceuticals for $1.7B
June 2, 2021
Biotechnology
MorphoSys AG has agreed to acquire Constellation Pharmaceuticals for $34.00 per share in cash, valuing the transaction at approximately $1.7 billion. The deal strengthens MorphoSys' hematology-oncology pipeline by adding Constellation's mid- to late-stage candidates (pelabresib/CPI-0610 and CPI-0209) and is supported by a strategic funding partnership with Royalty Pharma that provides significant upfront and milestone funding.
-
Chroma Color Corporation Acquires Ferco Color
October 21, 2025
Manufacturing
Chroma Color Corporation, a portfolio company of Arsenal Capital Partners, has acquired Ferco Color, a custom manufacturer of colorants, additives, and specialty compounds based in Chino, California. The undisclosed-term transaction expands Chroma's West Coast manufacturing footprint and broadens its colorant and additive technology capabilities, leveraging Ferco's on-site analytical laboratory and customer base across medical, packaging, aerospace and other end markets.
-
Astellas Pharma Acquires Xyphos Biosciences
December 26, 2019
Biotechnology
Astellas Pharma has acquired Xyphos Biosciences, gaining Xyphos' ACCEL convertible-CAR technology platform and immuno-oncology talent. The deal included $120 million paid at closing and potential milestone payments bringing the total transaction value to up to $665 million.
-
Bora Pharmaceuticals Acquires Upsher-Smith Laboratories
August 5, 2025
Pharmaceuticals
Bora Pharmaceuticals completed a 2024 acquisition of Upsher-Smith Laboratories for $210 million and is expanding the Maple Grove, Minnesota manufacturing site with a multi-year buildout. The investment includes installation of a Gerteis Macro-Pactor (operational Q3 2025) and development of 100,000 square feet of shell space to boost oral solid dose (OSD) contract development and manufacturing capabilities.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.